Nicolae Done
Education
Ph.D., health economics and policy, Johns Hopkins University; A.B., biochemical sciences, Harvard College
Summary of Experience
Dr. Done is a health economist with expertise in statistical and machine learning methodologies, which he applies to the study of a wide range of clinical and economic outcomes in health care. He has led and implemented analyses across the entire product lifecycle, from early-phase clinical trials to post-market real-world evidence (RWE) generation. He has experience in disease areas such as cardiology, neurology, hematology, infectious diseases and vaccines, dermatology, rheumatology, and rare genetic disorders. In his work, Dr. Done uses data from administrative claims, electronic health records, clinical trials, surveys, medical chart reviews, and the medical literature. His research encompasses a variety of study types, including policy evaluations, direct and indirect treatment comparisons, predictive analytics, risk adjustment and simulation, individualized medicine, disease epidemiology, burden of illness, disease treatment patterns, comparative-effectiveness research, systematic literature reviews, and economic modeling. Dr. Done’s research has been used to inform health care payer and delivery system policy, both in the US and globally; published in peer-reviewed journals; and presented at numerous clinical and economic research conferences. Prior to joining Analysis Group, Dr. Done was a research fellow at Boston University and a health economist at the Veterans Health Administration.
-
Impact of Differential Rates of Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Findings from a Longitudinal Cohort Analysis
The Journal of Prevention of Alzheimers, 2024
2024Chandler J, Georgieva M, Desai U, Done N, Gomez-Lievano A, Ye W, Zhao A, Eid D, Hilts A, Kirson N, Schilling T
-
Potential Implications of Slowing Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Estimates from Real-World Data
The Journal of Prevention of Alzheimer's Disease, 2024
2024Chandler J, Done N, Desai U, Georgieva M, Gomez-Lievano A, Ye W, Zhao A, Eid D, Hilts A, Kirson N, Schilling T
-
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis
Therapeutic Innovation & Regulatory Science, 2024
2024Signorovitch J, Zhang J, Brown D, Dunnmon P, Xiu L, Done N, Hsu K, Barbachano Y, Lousada I
-
Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls
Muscle & Nerve, 2024
2024Iff J, Nicolae Done N, Tuttle E, Zhong Y, Wei F, Darras BT, McDonald CM, Mercuri E, Muntoni F
-
Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998–2019
Vaccine, 2024
2024Mohanty S, Done N, Liu Q, Song Y, Wang T, Gaburo K, Sarpong EM, White M, Weaver JP, Signorovitch J, Weiss T
-
Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
PLOS One, 2024
2024Muntoni F, Signorovitch J, Sajeev G, Done N, Yao Z, Goemans N, McDonald C, Mercuri E, Niks EH, Wong B, Vandenborne K, Straub V, de Groot IJM, Tian C, Manzur A, Dieye I, Lane H, Ward SJ, Servais L
-
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population
JAMA Dermatology, 2023
2023Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, Done N, Swallow E
-
Economic Burden of Acute Otitis Media, Pneumonia, and Invasive Pneumococcal Disease in Children in the United States after the Introduction of 13-Valent Pneumococcal Conjugate Vaccines During 2014-2018
BMC Health Services Research, 2023
2023Hu T, Song Y, Done N, Mohanty S, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Weiss T
-
Incidence of Non-Invasive All-Cause Pneumonia in Children in the United States before and after the Introduction of Pneumococcal Conjugate Vaccines: A Retrospective Claims Database Analysis
Pneumonia, 2023
2023Hu T, Sarpong EM, Song Y, Done N, Liu Q, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T
-
Patient Characteristics Associated with All-Cause Healthcare Costs of Alopecia Areata in the United States
Journal of Medical Economics, 2023
2023Gao W, Mostaghimi A, Gandhi K, Done N, Ray M, Signorovitch J, Swallow E, Carley C, Wang T, Sikirica V
-
Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis
Acta Dermato-Venereologica, 2023
2023Done N, Bartolome L, Swallow E, Gao W, Carley C, Wang T, Mostaghimi A
-
Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial
Muscle & Nerve, 2022
2022Karam C, Brown D, Yang M, Done N, Zhu JJ, Greatsinger A, Bozas A, Vera-Llonch M, Signorovitch J
-
Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen
Muscle & Nerve, 2022
2022Karam C, Brown D, Yang M, Done N, Dieye I, Bozas A, Vera-Llonch M, Signorovitch J
-
Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018
BMC Public Health, 2022
2022Hu T, Song Y, Done N, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T
-
Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
Journal of Health Economics and Outcomes Research, 2022
2022Ray M, Swallow E, Gandhi K, Carley C, Sikirica V, Wang T, Done N, Signorovitch J, Mostaghimi A
-
All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022Mostaghimi A, Gandhi K, Done N, Ray M, Gao W, Carley C, Wang T, Swallow E, Sikirica V
-
Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018
BMS Infectious Diseases, 2022
2022Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E, Weiss T
-
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
Dermatology and Therapy, 2021
2021Papp KA, Soliman AM, Done N, Carley C, Wirtz EL, Puig L
-
June 6, 2024
-
February 26, 2024
-
April 10, 2023
-
March 29, 2022